Experience

Solid Biosciences

• United States
• Biotechnology Research
• 1 - 100 Employee

• Director

  • Feb 2022 - Present



Merck

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• • Jan 2021 - Feb 2022

  Vaccine Process DevelopmentUpstream Program Lead

• • Apr 2018 - Jan 2021

  Upstream Vaccine Process Development

• • Aug 2014 - Apr 2018

  Upstream Biologic Process Development I specialize in using my knowledge of metabolism to enhance productivity. I am heavily involved in technology (platform) development which can be applied to multiple projects. My objective is to identify the metabolic phenotypes that correlate with and encourage productivity. The rationale is straightforward. If productivity can be increased in a general sense, future pipeline projects can operate on shorter timelines. Furthermore, I serve as a department lead for systems biology, utilizing transcriptomics, metabomics, and fluxomics.In addition to technology development, I directly support pipeline projects. This includes clone selection, process ranging studies, and scale down development. Finally, I support regulatory filings through second person review, an effort performed immediately prior to Investigational New Drug (IND) applications. Show less



Vanderbilt University

• United States
• Higher Education
• 700 & Above Employee

• PhD Candidate

  • Aug 2009 - Dec 2014

  The objective of my research was to decrease the cost associated with the production of protein therapeutics. This was accomplished by decreasing production of wasteful byproducts, such as lactate. Specifically, I studied the mechanism as to why lactate was being produced in the presence of favorable growth conditions. Additionally, I elucidated the metabolic conditions associated with peak antibody production rates, and determined ways to foster the condition. Due to the industrial nature of my work, I personally collaborated with several industrial partners during my PhD. I collaborated most extensively with Amgen and Janssen. Show less



The Janssen Pharmaceutical Companies of Johnson & Johnson

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Intern, Cell Line Development

  • Oct 2013 - Dec 2013

  The objective of this work was to determine the shared metabolic characteristics of high titer achieving industrial clones in fed batch bioreactors. Once these characteristics are determined, both the cell line and its growth medium can be targeted for further enhancement to productivity. This research aims to provide a more directed approach to clonal generation, with the potential to not only yield high producing clones, but in less time. Ultimately, this will lead to reduced development costs. This highly collaborative study between Vanderbilt University and Janssen remains ongoing. Multiple publications have been yielded. Show less



Episcopal Diocese of Louisiana Hurricane Disaster Relief

• New Orleans, LA

• Group Leader

  • May 2009 - Jul 2009

  Provided hurricane disaster relief by the reconstruction of homes, primarily to the impoverished elderly, of greater New Orleans area. Provided hurricane disaster relief by the reconstruction of homes, primarily to the impoverished elderly, of greater New Orleans area.



Framatome

• France
• Nuclear Electric Power Generation
• 700 & Above Employee

• Intern

  • Jun 2005 - Jan 2007

  During the summer and winter of this time period, I worked for the Radiation Safety group at Areva, in the nuclear services branch of the organization. During the summer and winter of this time period, I worked for the Radiation Safety group at Areva, in the nuclear services branch of the organization.